Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Diana Ferraro, Maria Cellerino et al.|JAMA Neurology|2021Cited by 62
Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational studyDamiano Baroncini, G. Coniglio, Angelo Ghezzi et al.|Neurological Sciences|2022Cited by 32
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patientsAlvino Bisecco, Daniela Cargnelutti, Federica Matrone et al.|Journal of Neurology|2023Cited by 12
Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout durationDiana Ferraro, Carlo Pozzilli, Pietro Iaffaldano et al.|Journal of Neurology|2021Cited by 10
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders RegisterPaola Mosconi, Marinella Clerico, Tommaso Guerra et al.|Neurological Sciences|2023Cited by 9